Ralaniten
 | |
| Clinical data | |
|---|---|
| Other names | EPI-002 |
| Drug class | Nonsteroidal antiandrogen |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C21H27ClO5 |
| Molar mass | 394.89 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Ralaniten (developmental code name EPI-002) is an N-terminal domain antiandrogen which was never marketed.[1] It is a derivative of bisphenol A[2] and one of the four stereoisomers of EPI-001.[1] A prodrug of ralaniten, ralaniten acetate (EPI-506), was under development for the treatment of prostate cancer.[3]
See also
References
- ^ a b Myung JK, Banuelos CA, Fernandez JG, Mawji NR, Wang J, Tien AH, Yang YC, Tavakoli I, Haile S, Watt K, McEwan IJ, Plymate S, Andersen RJ, Sadar MD (2013). "An androgen receptor N-terminal domain antagonist for treating prostate cancer". J. Clin. Invest. 123 (7): 2948–60. doi:10.1172/JCI66398. PMC 3696543. PMID 23722902.
- ^ McEwan, Iainj; Monaghan, Amye (2016). "A sting in the tail: The N-terminal domain of the androgen receptor as a drug target". Asian Journal of Andrology. 18 (5): 687. doi:10.4103/1008-682X.181081. PMC 5000789. PMID 27212126.
{{cite journal}}: CS1 maint: unflagged free DOI (link) - ^ Maughan BL, Antonarakis ES (2015). "Clinical Relevance of Androgen Receptor Splice Variants in Castration-Resistant Prostate Cancer". Curr Treat Options Oncol. 16 (12): 57. doi:10.1007/s11864-015-0375-z. PMID 26537882.
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |
 | This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by expanding it. |